Introduction to soft tabletting of pellets and MCC pellet functionality
Soft tabletting of pellets is a specialized pharmaceutical compaction approach that enables the compression of coated pellet subunits into tablets while preserving pellet integrity and drug release performance. In this context, Multiple Unit Pellet Systems, or MUPS, combine the biopharmaceutical advantages of multiparticulates with the handling and patient benefits of tablets. MCC-based pellets play a central role in this technology because they deform plastically, cushion mechanical stress, and maintain coating functionality during compression. As a result, MCC pellets support robust tabletting, rapid tablet disintegration, and reliable dissolution behavior. Moreover, MUPS tablets reduce dose dumping risk, improve gastrointestinal distribution, and enhance patient compliance compared to conventional single-unit tablets. Consequently, soft tabletting of pellets has become a preferred strategy for modified-release, delayed-release, and combination products where performance consistency matters.
Summary of the publication on soft tabletting of pellets
The referenced publication investigates soft tabletting of pellets using MCC 102 and UICEL-A/102 as key pellet-forming and cushioning materials. The research focuses on producing MUPS tablets that achieve sufficient mechanical strength while preserving the original dissolution profile of coated pellets. Therefore, the work examines how pellet composition, morphology, and compaction behavior interact during tabletting.
The study uses sodium diclofenac as a model drug and applies a sustained-release polymer coating to the pellets. Both homogeneous pellets, produced by extrusion–spheronization, and inhomogeneous pellets, produced by dry powder layering on inert cores, were evaluated. As a result, the work provides insight into how pellet structure affects deformation and coating integrity during compression.
MCC 102 pellets demonstrated strong plastic deformation, which enabled softer compaction and better preservation of pellet structure. In contrast, UICEL-A/102 pellets showed higher porosity and swelling capacity. Consequently, UICEL-A/102-based MUPS disintegrated faster and released the drug more rapidly. However, this same swelling behavior limited their suitability for sustained-release applications.
When used in MUPS tablets, MCC 102 pellets achieved crushing strengths between 70 and 100 N while still disintegrating rapidly. Therefore, these tablets closely matched the dissolution behavior of uncompressed pellets. UICEL-A/102 pellets also formed mechanically stable tablets, but their higher swelling led to faster disintegration and altered release kinetics.
The study further highlights the importance of pellet production method. Inhomogeneous pellets layered onto inert starter cores responded differently to compression than homogeneous pellets. Notably, MCC-based starter cores supported softer tabletting and reduced coating damage. In contrast, sugar-based cores increased compaction stress and slowed tablet disintegration. Thus, the choice of core material directly influenced MUPS performance.
Overall, the publication demonstrates that successful soft tabletting of pellets requires careful alignment of pellet material, structure, and compaction parameters. Otherwise, coating damage or delayed disintegration may compromise therapeutic performance.
Role of Cellets, key insights, and material-related effects
In this publication, Cellets function as MCC-based inert starter cores for dry powder layering. Therefore, they provide a plastically deformable substrate that absorbs compression forces during tabletting. As a result, pellets layered onto Cellets show improved coating integrity and more predictable dissolution behavior compared to sugar-based cores.
The most important take-home message is that pellet material properties govern MUPS performance more than tablet hardness alone. Specifically, MCC 102 offers a balanced profile for sustained-release MUPS, whereas UICEL-A/102 favors immediate-release systems. Consequently, formulation goals should guide cellulose selection early in development.
Obstacles for MCC pellets include managing excessive densification during compression and controlling disintegration time. However, opportunities exist in tailoring MCC pellet porosity, size distribution, and deformation behavior. Advanced Cellets grades may further optimize cushioning and release stability.
Pellet sphericity improves flowability and die filling, which enhances tablet uniformity. At the same time, low friability limits coating damage and fines generation. Hardness requires precise adjustment, because excessive hardness delays disintegration, while insufficient hardness weakens tablets. Therefore, balancing these parameters remains critical for reliable soft tabletting of pellets.
Conclusion and outlook
Soft tabletting of pellets enables advanced MUPS dosage forms that combine multiparticulate performance with tablet convenience. This publication clearly shows that MCC pellets, especially Cellets, support soft compaction and stable drug release when formulation parameters align with material behavior. Although challenges remain, ongoing improvements in pellet engineering and MCC excipient design will expand MUPS applications. In the future, predictive formulation strategies and optimized MCC pellets will further strengthen soft tabletting of pellets as a core pharmaceutical technology.
References
[1] Dissertation, Balzano, Vincenzo; doi: 10.5451/unibas-004872301.
